Khiron CEO Alvaro Torres to Present at 2019 Canaccord Genuity U.S. Annual Growth Conference

Company Invited to Particpate in Strategic US Investor Conference

TORONTO, July 9, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a cannabis company with core operations in Latin America, announced today that the Company will be presenting at the 39th annual Canaccord Genuity Growth Conference, taking place in Boston, MA, August 7-8, 2019.

Khiron CEO, Alvaro Torres will present and answer questions from conference attendees, with Company president Chris Naprawa also in attendance for one on one meetings. A recording of the presention will be available and posted on the Khiron website.

Hosted by Canaccord Genuity, the conference brings together over 1,300 attendees, institutional investors and financial leaders to hear from growth companies, including in the health and life sciences sector. Conference details can be found by visiting: https://bit.ly/2Tg69rC

Recent Company Highlights

• Completes acquisition of Uruguay-based Nettagrowth International, advancing multi- country operator strategy, and gaining entry to Mercosur trading block
• Completes new lab facilities with initial capacity of 3 tonnes of extract per year
• Expands Kuida^® cosmeceutical brand distribution with Colombian drugstore chain
• Joins U.S. National Cannabis Roundtable with John Boehner, former Speaker of the House of Representatives

About Khiron

Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally. 

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox. 

Further information on Khiron Life Sciences can be found at https://investors.khiron.ca/

To be added to the distribution list, please email [email protected] with "Khiron" in the subject line.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Further information in respect of the Company can be found at www.khiron.ca.

SOURCE Khiron Life Sciences Corp.

Investor Contacts: Chris Naprawa, President, T: [phone], E: [email protected]; Phil Carlson, KCSA Strategic Communications, 212-896-1233, E: [email protected]; Media Contact: Jon Packer, Vice President, Communications, T: [phone], E: [email protected]